Best Stocks Under $2 Right Now It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $2.00 (2 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts. OverviewStocks Under $0.05Stocks Under $0.10Stocks Under $0.25Stocks Under $0.50Stocks Under $1Stocks Under $2Stocks Under $3Stocks Under $5Stocks Under $10Stocks Under $20Stocks Under $30Stocks Under $50Stocks On Sale 1. OS Therapies NYSE:OSTX$1.98 -0.02 (-1.00%) As of 03:40 PM EasternOS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. More about OS TherapiesMarket Capitalization$42.90 millionConsensus RatingBuyConsensus Price Target$18.00 (+809.1% Upside)Volume319,435 sharesAverage Volume946,346 sharesToday's Range$1.80▼$2.10 Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. 2. Stardust Power NASDAQ:SDST$0.50 +0.00 (+0.95%) As of 03:29 PM EasternStardust Power Inc is a vertically-integrated lithium refinery that engages in producing battery-grade lithium. The company was founded in 2022 and is based in Greenwich, Connecticut.Market Capitalization$28.95 millionConsensus RatingBuyConsensus Price Target$5.11 (+922.5% Upside)Volume169,965 sharesAverage Volume347,687 sharesToday's Range$0.49▼$0.513. Denison Mines NYSEAMERICAN:DNN$1.42 -0.01 (-0.35%) As of 03:41 PM EasternDenison Mines Corp. engages in the acquisition, exploration, and development of uranium bearing properties in Canada. Its flagship project is the Wheeler River uranium project covering an area of approximately 300,000 hectares located in the Athabasca Basin region in northern Saskatchewan. More about Denison MinesMarket Capitalization$1.27 billionP/E Ratio-141.50Consensus RatingBuyConsensus Price Target$3.00 (+112.0% Upside)Volume54.62 million sharesAverage Volume55.18 million shares4. Cardiol Therapeutics NASDAQ:CRDL$1.10 -0.05 (-4.35%) As of 03:40 PM EasternCardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. More about Cardiol TherapeuticsMarket Capitalization$90.87 millionP/E Ratio-2.82Consensus RatingBuyConsensus Price Target$8.40 (+663.6% Upside)Volume148,909 sharesAverage Volume237,439 shares5. GeoVax Labs NASDAQ:GOVX$1.00 0.00 (-0.15%) As of 03:37 PM EasternGeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. More about GeoVax LabsMarket Capitalization$13.81 millionP/E Ratio-0.18Consensus RatingBuyConsensus Price Target$12.90 (+1,192.8% Upside)Volume194,574 sharesAverage Volume589,966 shares6. Quince Therapeutics NASDAQ:QNCX$1.07 -0.06 (-5.31%) As of 03:23 PM EasternQuince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. More about Quince TherapeuticsMarket Capitalization$47.21 millionP/E Ratio-0.86Consensus RatingBuyConsensus Price Target$8.00 (+647.7% Upside)Volume74,904 sharesAverage Volume127,615 shares7. Reviva Pharmaceuticals NASDAQ:RVPH$0.87 -0.01 (-1.28%) As of 03:38 PM EasternReviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. More about Reviva PharmaceuticalsMarket Capitalization$40.47 millionP/E Ratio-0.78Consensus RatingBuyConsensus Price Target$10.00 (+1,055.0% Upside)Volume221,214 sharesAverage Volume1.32 million shares8. Immunic NASDAQ:IMUX$1.00 -0.28 (-21.88%) As of 03:40 PM EasternImmunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. More about ImmunicMarket Capitalization$95.82 millionP/E Ratio-0.81Consensus RatingBuyConsensus Price Target$13.20 (+1,220.0% Upside)Volume8.05 million sharesAverage Volume671,669 shares9. HIVE Digital Technologies NASDAQ:HIVE$1.68 -0.05 (-2.62%) As of 03:38 PM EasternHIVE Digital Technologies Ltd. operates as a cryptocurrency mining company in Canada, Sweden, and Iceland. The company engages in the mining and sale of digital currencies, including Ethereum Classic, Bitcoin, and other coins. More about HIVE Digital TechnologiesMarket Capitalization$285.45 millionP/E Ratio-33.50Consensus RatingBuyConsensus Price Target$7.64 (+356.3% Upside)Volume7.05 million sharesAverage Volume9.42 million shares10. Lucid Diagnostics NASDAQ:LUCD$1.29 +0.03 (+2.00%) As of 03:40 PM EasternLucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. More about Lucid DiagnosticsMarket Capitalization$135.44 millionP/E Ratio-1.13Consensus RatingBuyConsensus Price Target$3.50 (+172.3% Upside)Volume945,820 sharesAverage Volume860,383 shares11. Western Copper & Gold NYSE:WRN$1.11 +0.00 (+0.30%) As of 03:24 PM EasternWestern Copper & Gold Corp. operates as an exploration stage company, which engages in the acquisition, exploration, and future development of mineral resource properties. More about Western Copper & GoldMarket Capitalization$221.66 millionP/E Ratio-55.42Consensus RatingBuyConsensus Price Target$4.25 (+283.5% Upside)Volume240,743 sharesAverage Volume332,966 shares12. Ur-Energy NYSEAMERICAN:URG$0.76 +0.01 (+0.69%) As of 03:41 PM EasternUr-Energy Inc engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. More about Ur-EnergyMarket Capitalization$276.50 millionP/E Ratio-5.84Consensus RatingBuyConsensus Price Target$2.30 (+202.9% Upside)Volume1.87 million sharesAverage Volume4.68 million shares13. FibroBiologics NASDAQ:FBLG$1.10 +0.06 (+5.29%) As of 03:40 PM EasternFibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. More about FibroBiologicsMarket Capitalization$41.32 millionP/E Ratio-3.22Consensus RatingBuyConsensus Price Target$13.00 (+1,087.2% Upside)Volume159,772 sharesAverage Volume281,395 shares14. Rani Therapeutics NASDAQ:RANI$1.11 +0.00 (+0.06%) As of 03:39 PM EasternRani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. More about Rani TherapeuticsMarket Capitalization$63.85 millionP/E Ratio-1.05Consensus RatingBuyConsensus Price Target$12.33 (+1,010.4% Upside)Volume79,721 sharesAverage Volume713,623 shares15. Context Therapeutics NASDAQ:CNTX$0.87 -0.01 (-1.34%) As of 03:29 PM EasternContext Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. More about Context TherapeuticsMarket Capitalization$77.93 millionP/E Ratio-0.95Consensus RatingBuyConsensus Price Target$6.17 (+609.9% Upside)Volume65,216 sharesAverage Volume408,146 shares16. Aclaris Therapeutics NASDAQ:ACRS$1.38 +0.05 (+3.76%) As of 03:40 PM EasternAclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. More about Aclaris TherapeuticsMarket Capitalization$149.43 millionP/E Ratio-2.65Consensus RatingBuyConsensus Price Target$11.67 (+745.4% Upside)Volume309,606 sharesAverage Volume903,565 shares17. ProQR Therapeutics NASDAQ:PRQR$1.66 +0.03 (+1.84%) As of 03:34 PM EasternProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. More about ProQR TherapeuticsMarket Capitalization$174.65 millionP/E Ratio-5.19Consensus RatingBuyConsensus Price Target$8.75 (+427.1% Upside)Volume328,901 sharesAverage Volume600,481 shares18. Zura Bio NASDAQ:ZURA$1.58 +0.19 (+13.67%) As of 03:39 PM EasternZura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. More about Zura BioMarket Capitalization$108.03 millionP/E Ratio-2.98Consensus RatingBuyConsensus Price Target$14.67 (+828.3% Upside)Volume657,454 sharesAverage Volume386,613 shares19. Compass Therapeutics NASDAQ:CMPX$1.86 +0.02 (+1.09%) As of 03:39 PM EasternCompass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. More about Compass TherapeuticsMarket Capitalization$257.21 millionP/E Ratio-5.03Consensus RatingBuyConsensus Price Target$13.38 (+619.1% Upside)Volume289,659 sharesAverage Volume877,053 shares20. Prime Medicine NYSE:PRME$1.72 +0.13 (+7.81%) As of 03:39 PM EasternPrime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. More about Prime MedicineMarket Capitalization$226.25 millionP/E Ratio-0.84Consensus RatingBuyConsensus Price Target$13.38 (+675.4% Upside)Volume843,140 sharesAverage Volume1.29 million shares21. Lineage Cell Therapeutics NYSEAMERICAN:LCTX$0.49 +0.02 (+3.23%) As of 03:41 PM EasternLineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. More about Lineage Cell TherapeuticsMarket Capitalization$107.17 millionP/E Ratio-4.05Consensus RatingBuyConsensus Price Target$4.20 (+763.8% Upside)Volume968,196 sharesAverage Volume1.65 million shares22. ADC Therapeutics NYSE:ADCT$1.46 +0.05 (+3.17%) As of 03:40 PM EasternADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. More about ADC TherapeuticsMarket Capitalization$145.30 millionP/E Ratio-0.61Consensus RatingBuyConsensus Price Target$7.75 (+429.0% Upside)Volume115,954 sharesAverage Volume419,285 shares23. Annovis Bio NYSE:ANVS$1.49 +0.02 (+1.36%) As of 03:40 PM EasternAnnovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. More about Annovis BioMarket Capitalization$21.21 millionP/E Ratio-0.33Consensus RatingBuyConsensus Price Target$40.67 (+2,629.3% Upside)Volume209,483 sharesAverage Volume487,003 shares24. FiscalNote NYSE:NOTE$0.60 -0.01 (-1.50%) As of 03:40 PM EasternFiscalNote Holdings, Inc operates as technology company North America, Europe, Australia, and Asia. It combines artificial intelligence technology, machine learning, and other technologies with analytics, workflow tools, and expert research. More about FiscalNoteMarket Capitalization$96.19 millionP/E Ratio-2.71Consensus RatingBuyConsensus Price Target$2.66 (+346.4% Upside)Volume704,037 sharesAverage Volume3.17 million shares25. Vor Biopharma NYSE:VOR$0.68 +0.00 (+0.60%) As of 03:21 PM EasternVor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. More about Vor BiopharmaMarket Capitalization$85.40 millionP/E Ratio-0.41Consensus RatingBuyConsensus Price Target$8.86 (+1,194.9% Upside)Volume130,926 sharesAverage Volume433,010 shares More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
